| Balance Sheets | 2025-07-31 | |||
|---|---|---|---|---|
| Cash | 5,620,872 | |||
| Prepaid expenses and other current assets | 307,958 | |||
| Total current assets | 5,928,830 | |||
| Property and equipment, net | 397,921 | |||
| Total assets | 6,326,751 | |||
| Accounts payable and accrued liabilities | 983,311 | |||
| Total liabilities, all current | 983,311 | |||
| Preferred stock, value-Series BPreferred Stock | 0 | |||
| Preferred stock, value-Series CPreferred Stock | 0 | |||
| Common stock, 0.0001 par value 300,000,000 shares authorized 3,139,861 and 778,733 issued and outstanding as of july 31, 2025 and april 30, 2025, respectively | 314 | |||
| Additional paid-in capital | 66,581,071 | |||
| Accumulated deficit | -61,237,945 | |||
| Total stockholders equity | 5,343,440 | |||
| Total liabilities and stockholders equity | 6,326,751 | |||
Alzamend Neuro, Inc. (ALZN)
Alzamend Neuro, Inc. (ALZN)